Log In
BCIQ
Print this Print this
 

AG-221

  Manage Alerts
Collapse Summary General Information
Company Agios Pharmaceuticals Inc.
DescriptionInhibitor of mutated isocitrate dehydrogenase 2 (IDH2)
Molecular Target Isocitrate dehydrogenase 2 (IDH2)
Mechanism of ActionIsocitrate dehydrogenase 2 (IDH2) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$130.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/15/2010

Undisclosed

$130.0M

$120.0M

Get a free BioCentury trial today